Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A recent commentary tied behavioral health to cardiovascular outcomes, underscoring how depression, anxiety and chronic stress may affect risk and recovery in patients.
THE APEX TIMES
THE APEX TIMES
After reporting 48% revenue growth in its second quarter, Eli Lilly says additional developments have followed, including a UK regulatory approval and a new Medicare access program aimed at expanding patient reach.
THE APEX TIMES
A new Yahoo Finance column frames Eli Lilly’s obesity strategy as a broad “for every kind of patient” approach, reinforcing how crowded the weight-loss drug race has become. Lilly did not provide additional details in the referenced post.
THE APEX TIMES
Britain’s drug regulator authorized Eli Lilly’s oral GLP-1 medicine orforglipron on August 10, giving the company its first regulatory foothold in Europe for the obesity and weight-management class.
THE APEX TIMES
Pfizer shares have rebounded recently after years of underperformance, yet a closer look at returns versus earnings suggests the current valuation is not a slam-dunk either way.
THE APEX TIMES
Veeva Systems said Eli Lilly has committed to deploy Veeva Vault CRM globally, positioning the companies’ partnership around AI-enabled commercial workflows that can act on data, not just report it.
THE APEX TIMES
The settlement provides money to certain people who purchased Chantix. Claim submission closes September 14.
THE APEX TIMES
A recent market-news post argues that GLP-1 growth is driving demand beyond the usual duopoly of Eli Lilly and Novo Nordisk, spotlighting two other companies as potential beneficiaries.
THE APEX TIMES
Two of the biggest U.S. Medicare Advantage providers are reducing enrollment, indicating a shift toward protecting margins amid rising medical costs.
